Company to showcase AspyreRx™
Company to host sponsored education session on
Tuesday, October 31, 2023; A novel approach to treating type 2
diabetes
Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in
developing prescription digital therapeutics (PDTs) to treat
cardiometabolic diseases, today announced its participation in the
American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle
Medicine Annual Conference (LM2023), to be held October 29 to
November 1, 2023, in Denver, Colorado. The conference brings
together medical professionals, including physicians, healthcare
executives, academic faculty, and researchers from across the U.S.
and around the world, and seeks to drive the transformation of
healthcare by highlighting how shifting lifestyle related behaviors
can treat, prevent, and often reverse chronic disease.
Better Therapeutics’ platinum sponsorship of LM2023 reflects the
company’s shared commitment to showcasing evidence-based solutions
that restore health for those living with chronic conditions.
The company's focus at the meeting is to showcase AspyreRx, a
U.S. Food and Drug Administration (FDA) authorized PDT treatment
for adults with type 2 diabetes (T2D). AspyreRx is the first
prescription-only digital treatment to provide a proprietary form
of cognitive behavioral therapy (CBT) specifically for treating T2D
and is designed to overcome many of the limitations of traditional
in-person CBT. Attendees will have the opportunity to experience
the product firsthand and learn more about its clinical benefits at
the Better Therapeutics exhibition booth.
Additionally, Better Therapeutics is hosting a sponsored
education session on Tuesday, October 31, 2023 at 5:30pm - 6:30pm
MST, with speakers Mark Berman, MD FACLM, Chief Medical Officer,
and Elizabeth Pash, PhD, MS, RDN, LDN, Head of Medical Affairs,
presenting the clinical data, the mechanism of action, and
describing how patients will experience the treatment.
"We are honored to be a platinum sponsor at the LM2023 meeting.
This is a gathering of some of the most brilliant minds in the
field, and it's the perfect platform to showcase AspyreRx to an
audience that understands the importance of helping patients make
meaningful behavior change to improve health outcomes,” said Mark
Berman, MD, Chief Medical Office at Better Therapeutics. “We
believe our prescription digital therapeutic will revolutionize the
way we approach treatment of cardiometabolic diseases, and we're
excited to share it with the healthcare community."
For more information about LM2023, visit:
https://lifestylemedicine.org/project/lm2023/
For more information about AspyreRx, visit:
www.aspyrerx.com.
About AspyreRx
AspyreRx (formerly BT-001) was granted marketing authorization
by the U.S. Food and Drug Administration (FDA) in July 2023 as the
first prescription-only digital therapeutic to treat adults with
type 2 diabetes (T2D). AspyreRx is backed by robust data
demonstrating clinically meaningful and sustained reduction in A1c
as well as improvements in other markers of cardiometabolic health
when used up to 180 days. Using proven techniques that target the
underlying psychological, behavioral, and cognitive factors that
sustain or worsen T2D, AspyreRx is a self-paced, engaging
experience that patients can access from their smartphone. It is
prescribed by a healthcare provider in 90-day increments, with
proprietary CBT delivered digitally in a weekly step-by-step
process. Through interactive therapy lessons, skill-building
modules, weekly goal setting and tracking, patients connect changes
in behavior to improvements in blood sugar and other biometrics.
Each step in the experience builds on the prior to enable and
reinforce cognitive restructuring, building the emotional
resilience and acceptance needed to make enduring changes.
Indications for Use
AspyreRx is a prescription-only digital therapeutic device
intended to provide cognitive behavioral therapy to patients 18
years or older with type 2 diabetes. The device targets behavior to
aid in the management of type 2 diabetes in patients who are under
the care of a healthcare provider. AspyreRx provides cognitive
behavioral therapy as a treatment that should be used adjunctively
with standard of care.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics
company developing a novel form of cognitive behavioral therapy to
address underlying factors that sustain or worsen cardiometabolic
diseases. The Company has developed a proprietary platform for the
development of FDA-regulated, software-based solutions for T2D,
heart disease and other conditions. The CBT delivered by Better
Therapeutics’ PDT is designed to enable changes in neural pathways
of the brain so lasting changes in behavior become possible.
Addressing the underlying causes of these diseases has the
potential to dramatically improve patient health while lowering
healthcare costs. Better Therapeutics’ clinically validated mobile
applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “outlook,” “estimate,” “forecast,”
“project,” “continue,” “could,” “may,” “might,” “possible,”
“potential,” “predict,” “should,” “would” and other similar words
and expressions, but the absence of these words does not mean that
a statement is not forward-looking. The forward-looking statements
in this press release include, but are not limited to, statements
regarding Better Therapeutics’ expectations related to the efficacy
and potential benefits of PDTs, including AspyreRx and CBT, and
their potential treatment applications and their ability to improve
clinical outcomes, beliefs regarding the importance and potential
of behavior modification in diabetes treatment and statements
related to the needs of people living with T2D, among others. These
forward-looking statements are based on the current expectations of
the management of Better Therapeutics and are inherently subject to
uncertainties and changes in circumstances and their potential
effects and speak only as of the date of such statement. There can
be no assurance that future developments will be those that have
been anticipated. These forward-looking statements involve a number
of risks, uncertainties or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements including:
risks related to Better Therapeutics’ business, such as the
willingness of the FDA to authorize PDTs, for commercial
distribution and insurance companies to reimburse their use, market
acceptance of PDTs, including AspyreRx, the risk that the results
of previously conducted studies will not be interpreted favorably
by the FDA or repeated or observed in ongoing or future studies
involving Better Therapeutics’ product candidates and other risks
and uncertainties included under the header “Risk Factors” in
Better Therapeutics’ quarterly report on Form 10-Q for the quarter
ended June 30, 2023 filed with the Securities and Exchange
Commission (SEC) on August 9, 2023, and those that are included in
any of Better Therapeutics’ subsequent filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026498322/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media Enquiries: Emma Williams info@bettertx.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2024 to May 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From May 2023 to May 2024